What is the global market size of Research Antibodies and Reagents Market?

Research Antibodies and Reagents Market size was valued at USD 1.41 billion in 2021 and is poised to grow from USD 1.48 billion in 2022 to USD 2.17 billion by 2030, growing at a CAGR of 4.9% in the forecast period (2023-2030).

What is the key driver of Global Research Antibodies and Reagents Market?

Research and innovation depend on collaboration between academic institutions and businesses' R&D departments. These partnerships ensure the exchange of information and technology between academia and industry. The number of such collaborations has increased due to economic volatility and rapid technological change. Market participants focus on working with academic institutions to promote awareness of new analytical technology among students and researchers, particularly in the field of personalized medicine.

What is the key market trend for Global Research Antibodies and Reagents Market?

Personalized medicine has emerged as a significant research topic in the healthcare sector, leading to the detection, categorization, and treatment of diseases in new ways. Biopharmaceutical companies have significantly increased their R&D expenditures in personalized medicine, driving the demand for research antibodies and reagents. As personalized medicine gains popularity, there is a greater need for rapid, highly sensitive, and quantitative approaches to analyze proteins and associated post-translational modifications in clinical specimens.

Which region accounted for the largest share in Global Research Antibodies and Reagents Market?

North America dominates the research antibodies and reagents market, driven by increased investments in structure-based drug design, research projects involving proteins and biomolecules, and expanding R&D activities in genomics and proteomics.

Global Research Antibodies and Reagents Market Size, Share, Growth Analysis, By Technology(western blotting, flow cytometry), By Application(proteomics, drug development and Genomics) - Industry Forecast 2024-2031

Q: Who are the key vendors in the Global Research Antibodies and Reagents Market?

The research antibodies and reagents market is highly competitive and somewhat fragmented. Major industry participants continually implement various growth strategies, including innovations, mergers, acquisitions, collaborations, and partnerships. Notable players in the market include Thermo Fisher Scientific, Inc., Abcam plc., Merck KGaA, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Santa Cruz Biotechnology, Inc., GE Healthcare Life Sciences, BD Biosciences, BioLegend, Inc., R&D Systems, Inc., Sigma-Aldrich Corporation, Lonza Group Ltd., Promega Corporation, Qiagen N.V., Affymetrix, Inc., Novus Biologicals, LLC, Enzo Life Sciences, Inc., and OriGene Technologies, Inc.

Report ID: SQMIG35H2053 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 66 | Figures: 75

Global Research Antibodies and Reagents Market Insights

Global Research Antibodies and Reagents Market size was valued at USD 11.90 billion in 2022 and is poised to grow from USD 12.70 billion in 2023 to USD 21.33 billion by 2031, at a CAGR of 6.70% during the forecast period (2024-2031).

An unconjugated primary antibody that targets antigen is found using research antibodies and reagents. With the use of these items, proteins or biomolecules can be found, measured, and purified for use in a range of procedures, including flow cytometry, ELISA, western blotting, and immunohistochemistry. The rising demand for high-quality antibodies for research reproducibility is one of the key factors propelling the growth of the research antibodies and reagents market.

The expansion of proteomics and genomics research, as well as an increase in research and development activities to improve the overall course of diagnosis and treatment, are driving the growth of the research antibodies and reagents market. The increasing collaboration between industry and academia, as well as the growing stem cell and neurobiology research fields, all have an impact on the research antibodies and reagents market.

Furthermore, increased funding for research projects by for-profit and non-profit organisations, increased emphasis on biomarker discovery, government support, and growing interest in outsourcing all benefit the research antibodies and reagents market.

Furthermore, rising demand for personalized medicine and protein therapeutics, as well as emerging markets, provide profitable opportunities for research antibodies and reagents market players. On the other hand, cost and time-intensive antibody development processes, as well as pricing pressure on prominent players, are expected to stymie the growth of the research antibodies and reagents market. The research antibodies and reagents market is expected to face challenges from rising quality concerns and a lack of reproducible results during the forecast period.

US Research Antibodies and Reagents Market is poised to grow at a sustainable CAGR for the next forecast year.

Global Research Antibodies and Reagents Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

the research antibodies and reagents market is highly competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Thermo Fisher Scientific, Inc.', 'Abcam plc.', 'Merck KGaA', 'Bio-Rad Laboratories, Inc.', 'Cell Signaling Technology, Inc.', 'Agilent Technologies, Inc.', 'F. Hoffmann-La Roche Ltd.', 'Santa Cruz Biotechnology, Inc.', 'GE Healthcare Life Sciences', 'BD Biosciences', 'BioLegend, Inc.', 'R&D Systems, Inc.', 'Sigma-Aldrich Corporation', 'Lonza Group Ltd.', 'Promega Corporation', 'Qiagen N.V.', 'Affymetrix, Inc.', 'Novus Biologicals, LLC', 'Enzo Life Sciences, Inc.', 'OriGene Technologies, Inc.'

Research and innovation depend on collaboration between academic institutions and the R&D departments of businesses. These partnerships guarantee the movement of information and technology from the academic world to the business world and vice versa. The number of such collaborations has greatly increased as a result of the escalating economic volatility and the quickening pace of technological change. Due to the numerous uses for research-specific antibodies, Reagents, market participants are concentrating on working with academic institutions to promote student and researcher awareness of new analytical technology.

Many diseases are now being detected, categorised, and treated differently thanks to personalised medicine, which has emerged as a key topic of research in the healthcare sector. In oncology, these developments are particularly noticeable. Additionally, over the past five years, biopharmaceutical companies have almost doubled their R&D expenditures in personalized medicine; during the following five, this expenditure is predicted to rise by 33%. Rapid, highly sensitive, and quantitative approaches to examine proteins and associated post-translational alterations in clinical specimens are now more important than ever as personalized medicine gains popularity and helps to define individual patient treatments. Additionally, because gene variants might predict a patient's propensity to respond to a certain medicine, researchers are concentrating on identifying and understanding different proteins. Changes, genetic variations, and their connection to various diseases.

The market for research antibodies and reagents is dominated by North America due to an increase in investments for the creation of structure-based medication designs, a focus on research projects involving proteins, related biomolecules, and genes, and an expansion of research and development activities in the genomics and proteomics fields.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.